Sustained drug-free remission and persistent hypogammaglobulinemia in a patient with rheumatoid arthritis three years after discontinuing Rituximab treatment

Sustained drug-free remission and persistent hypogammaglobulinemia in a patient with rheumatoid arthritis three years after discontinuing Rituximab treatment

Bibliographic Details
Main Authors:	Marco Krasselt, Christoph Baerwald, Olga Seifert
Format:	Article
Language:	English
Published:	Sociedade Portuguesa de Reumatologia 2021-04-01
Series:	Acta Reumatológica Portuguesa
Subjects:	rheumatoid arthritis rituximab hypogammaglobulinemia dmards remission
Online Access:	http://www.actareumatologica.com/files/article/1353_sustained_drug_free_remission_and_persistent_hypogammaglobulinemia_in_a_patient_with_rheumatoid_arthritis_three_years_after_discontinuing_rituximab_treatment_file.pdf

Similar Items

ASSOCIATION OF SEROLOGICAL STATUS WITH THE FREQUENCY OF CLINICAL AND RADIOLOGICAL REMISSION IN RHEUMATOID ARTHRITIS
by: O.B. Iaremenko
Published: (2021-06-01)

BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study
by: Fiona Rayner, et al.
Published: (2021-07-01)

Late-onset hypogammaglobulinemia after rituximab therapy
by: O V Moskalets
Published: (2019-12-01)

Patterns of Response to Different Treatment Strategies in Seropositive Rheumatoid Arthritis Patients in a Tertiary Hospital in South‐Western Saudi Arabia: A Retrospective Study
by: AlOmair M, et al.
Published: (2021-08-01)

“Living a normal life”: a qualitative study of patients’ views of medication withdrawal in rheumatoid arthritis
by: Kenneth F. Baker, et al.
Published: (2019-06-01)

Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease
by: Joanna Tieu, et al.
Published: (2021-05-01)

Tonsillar granuloma associated with hypogammaglobulinemia
by: Aleksi Laajala, et al.
Published: (2020-05-01)

Tapering of biological antirheumatic drugs in rheumatoid arthritis patients is achievable and cost-effective in daily clinical practice: data from the Brussels UCLouvain RA Cohort
by: Stéphanie Dierckx, et al.
Published: (2020-04-01)

ADALIMUMAB DISCONTINUATION IN PATIENTS WITH RHEUMATOID ARTHRITIS AFTER ACHIEVING SUSTAINED REMISSION
by: N. V. Demidova, et al.
Published: (2018-07-01)

Rituximab-associated Hypogammaglobulinemia in pediatric patients with autoimmune diseases
by: Amer M. Khojah, et al.
Published: (2019-08-01)

Safety and efficacy of an Anti-CD20 Monoclonal antibody (RedituxTM) In Indian patients with seropositive rheumatoid arthritis
by: Arun Hegde, et al.
Published: (2018-01-01)

Rheumatoid Arthritis: Defining Clinical and Ultrasound Deep Remission
by: Corominas Hèctor, et al.
Published: (2020-01-01)

RHEUMATOID ARTHRITIS: THE PROBLEMS OF REMISSION AND THERAPY RESISTANCE
by: E. L. Nasonov, et al.
Published: (2018-07-01)

The long-term remission of rheumatoid arthritis with a single cycle of rituximab
by: Glišić Branislava, et al.
Published: (2012-01-01)

Clinical efficacy of the rituximab biosimilar Acellbia® 600 mg in patients with active rheumatoid arthritis in clinical practice
by: D. A. Kusevich, et al.
Published: (2019-01-01)

How to reduce costs of biological treatments in patients with Rheumatoid Arthritis: The Dutch experience
by: Piet L.C.M. van Riel
Published: (2016-01-01)

Efficacy of Rituximab on Rheumatoid Leptomeningitis as the First Symptom of Rheumatoid Arthritis
by: Mickaël Chouk, et al.
Published: (2021-04-01)

ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation
by: Debbie M. Boeters, et al.
Published: (2019-05-01)

Ultrasonographic findings of rheumatoid arthritis patients who are in clinical remission
by: Hadi Karimzadeh, et al.
Published: (2018-01-01)

Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
by: Mysler E, et al.
Published: (2021-06-01)

Evaluation of the clinical and anti-destructive effect of an anti-B cell preparation depending on concomitant therapy with basic anti-inflammatory drugs and glucocorticoids in patients with rheumatoid arthritis
by: A. V. Kudryavtseva, et al.
Published: (2019-12-01)

Tuberculosis Arthritis in the Wrist While Using Rituximab for Rheumatoid Arthritis Treatment
by: Ulusoy H, et al.
Published: (2020-09-01)

The Impact of Rituximab Therapy on the Chromosomes of Patients with Rheumatoid Arthritis
by: Šekib Sokolović, et al.
Published: (2010-05-01)

Evaluation of the clinical efficiency of tocilizumab versus rituximab therapy in patients with rheumatoid arthritis
by: Anastasia Sergeyevna Avdeyeva, et al.
Published: (2012-08-01)

Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach
by: Mireia Castillo-Vilella, et al.
Published: (2021-08-01)

Rheumatoid arthritis
by: Yoshiya Tanaka
Published: (2020-09-01)

Patient’s perspective of sustained remission in rheumatoid arthritis
by: Irazú Contreras-Yáñez, et al.
Published: (2017-09-01)

Leflunomide is equally efficacious and safe compared to low dose rituximab in refractory rheumatoid arthritis given in combination with methotrexate: results from a randomized double blind controlled clinical trial
by: Harindu Wijesinghe, et al.
Published: (2017-07-01)

PREDICTION OF TOCILIZUMAB AND RITUXIMAB EFFECTIVENESS IN RHEUMATOID ARTHRITIS
by: Volkava M. V.
Published: (2019-11-01)

CLINICAL AND ULTRASOUND ANKLE INVOLVEMENT IN RHEUMATOID ARTHRITIS IN REMISSION
by: Luminita Enache, et al.
Published: (2019-06-01)

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
by: M. A. Kotovskaya, et al.
Published: (2018-03-01)

Management of rheumatoid arthritis during pregnancy: challenges and solutions
by: Krause ML, et al.
Published: (2016-03-01)

EFFECT OF RITUXIMAB ON CARDIAC ELECTROPHYSIOLOGICAL PARAMETERS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: L. I. Feiskhanova
Published: (2018-11-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01)

Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled
by: Shin-ya Kawashiri, et al.
Published: (2017-05-01)

Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis
by: S. Chandrashekara, et al.
Published: (2016-02-01)

Rituximab Therapy in Renal Amyloidosis Secondary to Rheumatoid Arthritis
by: Levent Kilic, et al.
Published: (2018-11-01)

The importance of early arthritis in patients with rheumatoid arthritis
by: Georgiana Iftimie, et al.
Published: (2018-10-01)

Rheumatoid arthritis and lymphoma: the role of disease-modifying anti-rheumatic drugs
by: Detrick, Jordan
Published: (2018)

Demographics and clinical characteristics associated with sustained remission and continuation of sustained remission in patients with rheumatoid arthritis treated with adalimumab
by: Noriko Kimura, et al.
Published: (2019-03-01)